Global Reperfusion Injury Therapeutic Pipeline Review, H1 2014 - 7 Companies & 15 Drug Profiles
M2 - Tue Jul 01, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ffkhq3/reperfusion) has announced the addition of the "Reperfusion Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - NeuroVive Pharmaceutical AB - Scynexis, Inc. - Apeptico Forschung und Entwicklung GmbH - Stealth Peptides Inc. - Eustralis Pharmaceuticals Ltd - Nyken BV - Vasade Biosciences, Inc. Drug Profiles - cyclosporine - MTP-131 - GNX-5086 - bucillamine - Recombinant Protein to Inhibit CXCL for Cardiovascular and CNS Disorders - EUC-002 - AP-301 - NYK-1112 - Type 5 Adenylyl Cyclase Inhibitors - Small Molecule for Reperfusion Injury - MitoSNO - PVIIA - RIIIK - Small Molecules to Inhibit Cyclophilin D for Ischemia Reperfusion Injury, Neurodegenerative Diseases, And Trauma - Synthetic Peptides to Activate Complement C3 for Immunology, Cardiovascular and CNS Disorders For more information visit http://www.researchandmarkets.com/research/ff...eperfusion
Ischemic Stroke - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2fmkd/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - BioTime, Inc. - Athersys, Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - FibroGen, Inc. - Panacea Pharmaceuticals, Inc. - Acorda Therapeutics, Inc. - Laboratoires Pierre Fabre SA - Mitsubishi Tanabe Pharma Corporation - Celgene Corporation - Neuralstem, Inc. - Mesoblast Limited - Torrent Pharmaceuticals Limited - Pluristem Therapeutics Inc. - Huons Co., Ltd. - NeuroVive Pharmaceutical AB - Digna Biotech, S.L. - AGY Therapeutics, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Virogenomics, Inc. - Stemedica Cell Technologies, Inc. - Shin Poong Pharm Co., Ltd. - Tarix Pharmaceuticals LTD. - International Biotechnology Center Generium - MediaPharma s.r.l. For more information visit http://www.researchandmarkets.com/research/c2...mic_stroke
NeuroVive Pharmaceutical and A1M Pharma initiate research collaboration
Business Wire - Tue Mar 25, 2:37AM CDT
Regulatory News:
NeuroVive Pharmaceutical: NeuroVive starts collaboration to evaluate IPO of subsidiary in Taiwan
Business Wire - Mon Mar 10, 2:42AM CDT
Regulatory News: